COAG: Hemab Therapeutics Holdings, Inc.
Performance
COAG +25.91%
Watchlist
Select an item
Summary
COAG at a glance
COAG returned +25.91% since May 1, 2026. Its worst drop since then was -48.36%, smaller than 25% of stocks on Redstone, and its Sharpe ratio of 0.91 beats 71% of stocks on Redstone. It hasn't paid a dividend since it listed.
Current Drawdown
-22.08%
Rolling Volatility
81.92%
Actions
Metrics
Risk Indicators*
Alpha75.25%
Beta0.73x
Sharpe0.91
Sortino1.29
Omega1.17
Calmar0.54
Martin3.35
Profile
About COAG
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease.
- Sector
- Health Care
- Industry
- Biological Products, (no Diagnostic Substances)
- Market cap
- $2.0B
- Listed
- May 2026
- Headquarters
- Cambridge, MA
- Website
- hemab.com
Comparisons